Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-directed, effector cell-mediated tumor destruction.

P M Sondel1, J A Hank

  • 1Departments of Human Oncology, Pediatrics, and Genetics, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA. pmsondel@facstaff.wisc.edu

Hematology/Oncology Clinics of North America
|October 26, 2001
PubMed
Summary

Monoclonal antibody (mAb) therapies show promise for antitumor efficacy, especially in minimal residual disease settings. Combining mAbs with cytokines like IL-2 can enhance immune cell activation for greater antitumor effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy.

bioRxiv : the preprint server for biology·2023
Same author

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.

Cancer immunology, immunotherapy : CII·2023
Same author

Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction.

Immunology today·2014
Same author

An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood.

Journal of immunological methods·2012
Same author

Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.

Human gene therapy·2002
Same author

Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) are a developing strategy for antitumor treatments.
  • Current research explores mAb efficacy in preclinical and clinical settings.

Purpose of the Study:

  • To evaluate the antitumor efficacy of mAb-based strategies.
  • To investigate the role of mAbs in minimal residual disease (MRD).
  • To assess the combination of mAbs with recombinant cytokines for enhanced immunologic effects.

Main Methods:

  • Utilizing preclinical murine models to test mAb antitumor strategies.
  • Investigating the combination of mAbs with recombinant cytokines (IL-2, IL-12, GM-CSF).
  • Analyzing the recruitment of host immune effector cells by mAbs.

Related Experiment Videos

Main Results:

  • mAb treatment demonstrates antitumor efficacy in animal models and some clinical settings.
  • Preclinical models indicate optimal mAb effectiveness in the minimal residual disease setting.
  • Combining mAbs with cytokines augments immunologic effects by activating effector cells.

Conclusions:

  • Monoclonal antibody therapy shows potential as an antitumor strategy, particularly in MRD.
  • Cytokine combinations with mAbs can enhance immune-mediated antitumor responses.
  • Further clinical trials are investigating these immunotherapeutic approaches.